Skip to main content

X4 Pharmaceuticals, Inc 10-Q for FY2026 Q3

X4 Pharmaceuticals, Inc (XFOR)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

X4 Pharmaceuticals, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

X4 Pharmaceuticals, Inc. said the FDA supports reducing its Phase 3 4WARD trial from 176 to 126 participants while maintaining adequate power; nine-month 2026 net loss was $56.6 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$2.8M
up 75.0% from $1.6M a year earlier
Net loss
$20.2M
compared with a net loss of $29.82M a year earlier
Diluted EPS
-$0.16
compared with -$0.69 a year earlier